Faes Farma : Q2 operating performance in line. FY 2023 outlook maintained
>Sales momentum remains soft and margins deteriorate - Q2 2023 sales reached € 118m (+3% y-o-y vs +2% in Q1 2023, +2% in Q4 2022 and -6% in Q3 2022). By division, sales of traditional products in Spain posted some sequential improvement yet remained in the red (-1% y-o-y vs -4% in 1Q 2023, -7% in Q4 2022 and -9% in Q3 2022), reflecting lower dynamism in Bilastine (facing generic competition) and Mesalazine partially offset by Calcifediol. Sales in Portugal posted a sl...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.